Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 9/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.49 |
| ▸ | MAOA | P21397 | 3/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6386328 | 0.91 | MAOB (0.46) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL3643405 | 0.85 | MAOB (0.54) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL4012665 | 0.85 | CYP1A2 (0.50) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL6615417 | 0.83 | MAOB (0.40) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL9650321 | 0.83 | LTB4R (0.57) | CYP1A2MAOBALOX5MCL1NR4A2 | |
| SCHEMBL2514457 | 0.81 | HIF1A (0.58) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL8588173 | 0.81 | LMNA (0.58) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL27859426 | 0.81 | ALOX5 (0.50) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL8070497 | 0.80 | MAOB (0.61) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL6702208 | 0.80 | LMNA (0.56) | LMNACYP1A2PTGS1SLC6A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598266-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090176863-A1 | THIOPHENE DERIVATIVE PPAR MODULATORS | MANTLO NATHAN BRYAN | 2009-07-09 | — | — | US | disclosed |
| US-7544707-B2 | Bicyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-06-09 | — | — | US | disclosed |
| US-7504433-B2 | Thiophene derivative PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-03-17 | — | — | US | disclosed |
| US-20090054479-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | CONNER SCOTT EUGENE | 2009-02-26 | — | — | US | disclosed |
| US-7495020-B2 | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | MERCK & CO., INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495020-B2 | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | MERCK & CO., INC. (US) | 2009-02-24 | — | — | US | disclosed |
| EP-1480642-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | LILLY CO ELI (US) | 2008-11-26 | — | — | EP | disclosed |
| US-20080167310-A1 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) | GOSSETT LYNN STACY | 2008-07-10 | — | — | US | disclosed |
| US-20080146631-A1 | OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | BROOKS DAWN ALISA | 2008-06-19 | — | — | US | disclosed |
| US-6242644-B1 | FOR TREATING THROMBOSIS, APOPLEXY, CARDIAC INFARCTION, INFLAMATION AND ARTHEROSCLEROSIS | HOFFMANN-LA ROCHE INC. | 2001-06-05 | — | — | US | disclosed |
| US-20010001799-A1 | N-(4- carbamimidoyl-phenyl) -glycine derivatives | ACKERMANN JEAN (CH) | 2001-05-24 | — | — | US | disclosed |
| US-6133471-A | Process for producing chromans | KURARAY CO., LTD. (JP) | 2000-10-17 | — | — | US | disclosed |
| US-6130341-A | Process for producing chromans | KURARAY CO., LTD. (JP) | 2000-10-10 | — | — | US | disclosed |
| US-6090836-A | DIETETICS; ADJUSTMENT OF TRIGLYCERIDE CONCENTRATION | MERCK & CO., INC. (US) | 2000-07-18 | — | — | US | disclosed |
| WO-2000035858-A1 | PHENYLGLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-22 | — | — | WO | disclosed |
| EP-0891974-A1 | Process for producing chromans | KURARAY CO., LTD. (JP) | 1999-01-20 | — | — | EP | disclosed |
| EP-0882029-A1 | HETEROCYCLIC DERIVATIVES AS ANTIDIABETIC AND ANTIOBESITY AGENTS | Merck & Co., Inc. (US) | 1998-12-09 | — | — | EP | disclosed |
| EP-0846683-A1 | 4-Hydroxy-piperidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1998-06-10 | — | — | EP | disclosed |
| WO-1997028137-A1 | HETEROCYCLIC DERIVATIVES AS ANTIDIABETIC AND ANTIOBESITY AGENTS | MERCK & CO., INC. (US) | 1997-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176863-A1 | THIOPHENE DERIVATIVE PPAR MODULATORS | PPARA, PPARG, PPARD | LMNA 4004/4885CYP1A2 346/4885PTGS1 779/4885 |
| US-20080167310-A1 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) | PPARG, PPARA, PPARD | LMNA 2660/4885CYP1A2 567/4885PTGS1 327/4885 |
| US-20080146631-A1 | OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | PPARA, PPARG, PPARD | LMNA 1860/4885CYP1A2 278/4885PTGS1 1627/4885 |
| US-20010001799-A1 | N-(4- carbamimidoyl-phenyl) -glycine derivatives | GLRA1, NGLY1, GLS | LMNA 2613/4885CYP1A2 4088/4885PTGS1 451/4885 |
| US-20090054479-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | PPARA, PPARG, PPARD | LMNA 1331/4885CYP1A2 583/4885PTGS1 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.